Login to Your Account



Analyst: Gilead/Triangle's HIV Drug, Facing GSK's, May Need More Trials

By Randall Osborne


Monday, December 9, 2002
Almost as if to provide a metaphor for HIV treatment strategy - drug combination is the weapon of choice for fighting the infection - two major players said last week they plan to join forces in a $464 million merger whereby Gilead Sciences Inc. will acquire Triangle Pharmaceuticals Inc. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription